David Allison, Ph.D. is a Managing Director at Westlake BioPartners and has over 15 years of healthcare investing, company formation, and translational research experience. Immediately prior to joining Westlake, David was a Partner at 5AM Ventures in San Francisco and has previously been on the investment teams at Versant Ventures, Split Rock Partners, and PTV Healthcare Capital.
Throughout his career, David has been involved in investments in companies that have gone on to make important medicines for patients, achieve public offerings, and ultimately lead to acquisitions. Such select companies include CinCor Pharma (NASDAQ: CINC, acquired by AstraZeneca), Crinetics (NASDAQ: CRNX), Impel Neuropharma (NASDAQ: IMPL), Inipharm, Magnetic Insight, Neurogastrx, Portal Instruments, Radionetics Oncology, and Recludix Pharma. David received his Ph.D. in Bioengineering from Rice University and a B.S.E in Biomedical Engineering from The University of Iowa with honors.